Alex Brill, a senior fellow at the American Enterprise Institute and CEO of Matrix Global Advisors, recently sat down with CAPD spokesperson Maura Keefe to discuss his latest report for CAPD.
“The rebate rule came out of a concern about rising drug prices,” said Brill. “But it is a policy that is chock full of unintended consequences. If it were implemented, we’d have fewer discounts. That’s definitely not going to lower overall spending in the healthcare sector.”
In response to the FTC’s request for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers, MGA’s Alex Brill submitted a letter detailing his findings.
This week, three publications in the healthcare policy and regulatory affairs industries referenced MGA’s recent report on the potential savings from accelerating US approval of complex generics.
Matrix Global Advisors (MGA) today released a new report, “Potential Savings from Accelerating US Approval of Complex Generics,” by MGA founder and CEO Alex Brill.
